Indian pharma industry estimated to grow nine to 11 per cent in 2021-22: ICRA
The Indian pharma industry is estimated to grow at nine to 11 percent in 2021-22 and in the next few quarters, it will be driven by domestic and emerging markets, according to ratings agency ICRA.
January 6, 2022
by ExpressPharma
Indian pharma: Driving excellence in quality and patient centricity
The Indian pharma industry has recorded tremendous growth over the decades, more so during the pandemic. The Indian pharma sector has continued to be one of the key stakeholders in the pharma supply chain, providing access to affordable and quality ...
December 4, 2020
by expresspharma
The Biden effect on India Pharma Inc
Stakeholders share their views and insights on the impact of a change of guard at the White House and outline India Pharma Inc's expectations from the Biden administration.
December 2, 2020
by expresspharma
Pharma exports record 10 per cent growth in dollar terms during Q1 FY’21
Pharmexcil requests the government to resume Air India flights to Africa as it is the second-largest importer of Indian pharma products.
July 20, 2020
by expresspharma
COVID-19 restricts Indian pharma export growth to 7.6 per cent in FY’20
India exported pharma products to 202 destinations in FY’20.
May 11, 2020
by expresspharma
Evolution of Indian Pharma Regulatory Framework
Dr Gopakumar G Nair, CEO, Gopakumar Nair Associates, gives insights on the transformational journey of India’s pharma industry coming to par with the global standards, since independence
August 7, 2017
by expressbpd
Indian pharma exports to US may go up in 2017-18: Report
The pharma industry (IPI) earns around 70 per cent of its revenues from sale of generic drugs and generates around 50 per cent of its revenues from exports
July 19, 2017
by expressbpd
Veeva releases survey on digitalisation in Indian pharma
Reports reveals 66 per cent of respondents believe digital will become core to company strategy over the next three years
May 5, 2017
by financialexpress
Indian pharma industry continues to face headwinds; aggregate growth expected to come down to single
ICRA expects growth trajectory for Indian pharmaceutical industry to moderate on back of slowing growth from the US, increased competition, and regulatory overhang along with base effect catching up.
March 8, 2017
by expressbpd